In vitro activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis

Kekkaku

Volumn 71, Issue 8, 1996, Pages 459-464

  Sato, Katsumasa ^a   Tomioka, Haruaki ^a   Saito, Hajime ^a   Kawahara, Shin ^a   Hidaka, Takayoshi ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Cross resistance; KRM 1648; Mycobacterium tuberculosis

Indexed keywords

BENZOXAZINONE DERIVATIVE; RIFABUTIN; RIFALAZIL; RIFAMYCIN; RIFAMYCIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; DRUG SCREENING; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ANTIBIOTICS, ANTITUBERCULAR; MYCOBACTERIUM TUBERCULOSIS; RIFABUTIN; RIFAMPIN; RIFAMYCINS;

EID: 0029819467     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Saito H, Tomioka H, Sato K, et al. : In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother. 1991 ; 35 : 542-547
2. Tomioka H, Saito H, Fujii K, et al. : In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method. Antimicrob Agents Chemother. 1993 ; 37 : 67-70.
3. Fujii K, Saito H, Tomioka H, et al. : Mechanisms of action of antimycobcaterial activity of the benzoxazinorifamycin KRM-1648. Antimicrob Agents Chemother. 1995 ; 39 : 1489-1492.
4. Tomioka H, Saito H, Sato K, et al. : Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother. 1992 ; 36 : 387-393.
5. Yamamoto Y, Saito H, Tomioka H, et al. : In vitro and in vivo activities of KRM-1648, a newly synthesized benzoxazinorifamycin, against Mycobacterium marium. Zbl Bakt. 1992 ; 277 . 204-209.
6. Tomioka H, Saito H, and Hidaka T : In vivo antileprosy activity of the newly synthesized benzoxazinorifamycin, KRM-1648. Int J Lepr. 1993 ; 61 : 255-258
7. Emori M, Saito H, Sato K, et al. : Therapeutic efficacy of a benzoxazinorifamycin, KRM - 1648, against experimental Mycobacterium avium infection induced in rabbits. Antimicrob Agents Chemother. 1993 ; 37 : 722-728.
8. Saito H, Tomioka H, Sato K, et al. : Therapeutic efficacy of benzoxazinorifamycin, KRM-1648, in combination with other antimicrobials against Mycobacterium leprae infection induced in mice. Int J Lepr. 1994 ; 62 : 43-47.
9. Saito H, Tomioka H, Sato K, et al. : Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice. Antimicrob Agents Chemothr. 1995 ; 76 : 51-58.
10. Hirata T, Saito H, Tomioka H, et al. : In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 ; 39 : 2295-2303.
11. Luna-Herrera J, Reddy MV, and Gangadharam PRJ : In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrugresistant tubercle bacilli. Antimicrob Agents Chemother. 1995 ; 39 : 440-444.
12. Klemens SP, and Cynamon MH : Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother. 1996 ; 40 : 298-301.
13. Yamamoto T, Amitani R, Suzuki K, et al. : In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1996 ; 40 : 426-428.
14. Yamamoto T, Amitani R, Suzuki K, et al. : Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. Antimicrob Agents Chemother. 1996 ; 40 : 429-432.
15. Ji B, Lounis N, Truffot-Pernot C, and Grosset J. : How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? Antimicrob Agents Chemother. 1996 ; 40 : 437-442.
16. McClatchy JK : Susceptibility testing of mycobacteria. Lab. Med. 1978 ; 9 : 47-52.